theMednetRegister

Medical Oncology

Pediatric Hematology/Oncology   

Questions discussed in this category

Do you utilize D-dimer to inform anticoagulation duration in the treatment of VTE?
Provoked or unprovoked VTE: Do you use D-Dimer (or even repeat imaging to reassess residual clot) in any capacity to guide anticoagulation duration? E...
4 Answers available
In an adult patient with asymptomatic, isolated neutropenia in whom you suspect a Duffy null phenotype, at what ANC or in what situations would you do a bone marrow to look for other etiologies of neutropenia?
1 Answer available
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
When now would you consider regimens such as BV-AVD or BrECADD in advanced stage HL?
3 Answers available
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
6 Answers available
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
2 Answers available
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
5 Answers available
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
4 Answers available
Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?
4 Answers available
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
Do you routinely use PET/CT during treatment, such as after cycle 2, to evaluate for response? How would nivolumab treatment affect PET/CT interpretat...
6 Answers available
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
3 Answers available
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
There is conflicting data on whether the "surprise question" performs adequately enough.  Do you use this or other screening tools alone, or in c...
3 Answers available
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
1 Answer available
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
2 Answers available
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
Would you consider holding, deferring, or skipping treatment? For hepatitis, how would determine if toxicity was immunotherapy vs chemotherapy relate...
2 Answers available
Is there evidence to support or argue against intermittent fasting for cancer patients?
3 Answers available
How do you differentiate demoralization from depression during cancer treatment?
2 Answers available
How will you use Pola-R-CHP in the frontline treatment of DLBCL?
Given the POLARIX study data presented at ASH 2021 and subsequent longer term follow up, will this replace R-CHOP as the standard of care therapy in y...
4 Answers available
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
1 Answer available
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
Do you consider supportive transfusions, and if so, have you been successful with keeping patients on hospice while receiving transfusions? Do you us...
2 Answers available
What is your surveillance protocol for patients with common variable immunodeficiency receiving chronic IVIG therapy?
Is there a target IgG level to aim for? What should hematologists be aware of in monitoring these patients?
1 Answer available
What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?
1 Answer available
In pure red cell aplasia, does peripheral blood-positive IgG for parvovirus have significance if persistently positive on retesting, but IgM and PCR are negative?
The patient has a recurrence of the disease despite tapering prednisone and cyclosporine. Bone marrow exams x2 without MDS. Testing for all other caus...
1 Answer available
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
1 Answer available
What systemic therapy would you offer a patient with metastatic melanoma who is BRAF WT and developed metastases while on adjuvant nivolumab?
2 Answers available
What are your top takeaways in Classical Hematology from ASH 2024?
9 Answers available
What are your top takeaways in Hematologic Malignancies from ASH 2024?
12 Answers available
What are the best radiation therapy options for a young adult with 3 brain metastases from myeloid sarcoma that hasn’t responded well to intrathecal therapy?
Specifically, what dose and treatment volumes are recommended?
1 Answer available
How do you approach the treatment of teen patients with recurrent mediastinal germ cell tumor who have failed standard therapy, radiation, and HD therapy/stem cell rescue?
Is there a role for immunotherapy, anti-angiogenesis, or TKIs? Can you use immune checkpoint inhibitors in combination with lenvatinib? 
1 Answer available
What is your strategy for treating headaches in patients with history of brain tumor?
Specifically, headaches thought not to be related to increased ICP.
2 Answers available
How do you approach anti-seizure medication management when it was started by another team for a seizure-naive patient before/after craniotomy for a tumor?
1 Answer available
For patients with newly diagnosed brain metastases without a history of seizure activity, do you routinely start anti-seizure medication?
If so, how long do you continue medication and when do you discontinue? Does treatment with surgical resection versus radiation alone change your mana...
1 Answer available
Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?
1 Answer available
What is the utility of granulocyte infusions in patients with neutropenia and severe infection?
1 Answer available
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
Is there a role for nelarabine and venetoclax in this setting?
1 Answer available
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
Do you discuss the risk of sickle cell crises with G-CSF? What about for patients with sickle cell trait?
1 Answer available
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
4 Answers available
How do you counsel patients with locally advanced malignancies who have ECOG 3-4?
How do you advise patients who strongly desire chemotherapy?
3 Answers available
How often do you monitor AML patients after transplant for recurrence?
1 Answer available
What is your preferred graft source and conditioning regimen in a patient with Fanconi anemia and AML undergoing stem cell transplant?
Is there a role for non-myeloablative regimens?
1 Answer available
How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?
4 Answers available
What infections should we rule out in patients who develop diarrhea on immunotherapy?
Chemotherapy is associated with acquiring C diff colitis. Does immunotherapy share that same risk and necessitate ruling out infection prior to anti-d...
1 Answer available
How would you manage a patient less than 40 years old with an incidentally found LGG, IDH mutated, 1p19q intact, s/p STR?
Would you offer radiation and chemotherapy, vorasidenib, or observation?
4 Answers available
How would you treat suspected secondary HLH in patients whom etoposide is contraindicated?
No clear inciting etiology found. Would you consider dexamethasone +/- cytokine blockade (IL-1, IL-6, or IFN-g)? What do you think about the data for...
1 Answer available
Is it appropriate to substitute vincristine for vinblastine in ABVD for systemic therapy of Hodgkins lymphoma?
Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...
1 Answer available
Does your evaluation of a young person with spontaneous upper extremity DVT vary as compared to lower extremity DVT?
Do you do additional workup for venous obstruction or any other different testing/evaluation?
1 Answer available
Do you use direct oral anticoagulants to treat port-a-cath related VTE in patients with an active malignancy?
Do social or economic factors (i.e., relative cost of acquiring LMWH, the patient being injection averse) affect your decision to use DOACs? Do you s...
1 Answer available
How do you prescribe a steroid taper for radiation and checkpoint inhibitor related pneumonitis?
I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...
2 Answers available
How do you approach patients with lymph node positive osteosarcoma of the extremities for neoadjuvant chemotherapy?
1 Answer available
What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
1 Answer available
What is your target Hgb/Hct for women who are pregnant and have sickle cell disease in whom you are doing scheduled transfusions?
2 Answers available
What approach do you use when treating adult diffuse gliomas with H3-G34 mutations, now classified into their own category under the 2021 glioma guidelines?
Do you treat this similarly to IDH-Wildtype GBM with the STUPP regimen? Is there any role of less-intensive paradigms, such as 59.4 Gy/33 fx?
1 Answer available
How would you approach patients with primary cardiac sarcomas for adjuvant systemic treatment?
How do we approach patients with rare tumors given the paucity of data?
2 Answers available
What are magic mouthwash alternatives that you would recommend?
There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?
9 Answers available
Should all patients with a remote history of immunotherapy, chemotherapy and/or radiation therapy have a baseline TTE regardless of ASCVD risk?
2 Answers available
How do you manage patients blood pressures while on anti-angiogenic TKIs?
Do you insist on ambulatory/home blood pressures to rule in/out white coat hypertension? Does your practice have a system to log patients' BPs to supp...
1 Answer available
How do you manage steroid-refractory acute GVHD following allogeneic transplant?
What criteria do you use to define steroid-refractory disease? Does your management different by organ system involved - GI vs skin vs other?
1 Answer available
What, if any, cardioprotective measures beyond dexrazoxane may be used to minimize cardiac risk during or after chemo- or radio-therapy?
Are there other measures, pharmocologic or adjunctive, that can be used or are under investigation to mitigate cardiotoxicity related to chemo- or rad...
2 Answers available
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
The patient presented with a numb chin, more to the right of his face; an MRI did report mandibular nerve opacity, which is non-specific per neuro-rad...
1 Answer available
How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?
1 Answer available
What is your preferred conditioning regimen for fit patients with high-risk MDS undergoing MUD allogeneic stem cell transplantation?
How do you choose between RIC compared to MAC? Is there evidence for one over the other in an otherwise healthy, young patient? Do you include hypome...
1 Answer available
How do you approach autologous stem cell transplant in T-cell lymphomas/PTCL after induction chemotherapy with achievement of CR1?
NCCN says "consider autologous HCT" while retrospective data seems to support SCT in most histologies like AITL
1 Answer available
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?
1 Answer available
How do you approach treatment of sub-total resected ZFTA fusion ependymoma after radiation therapy in a young adult?
Do you recommend adjuvant chemotherapy after radiation treatment?
1 Answer available
What is your approach to working up diarrhea in an immunocompromised patient?
1 Answer available
How do you approach a young patient with undifferentiated pleomorphic sarcoma of the upper extremity who developed ifosfamide-induced nephrotoxicity after two cycles of adjuvant AIM chemotherapy?
Would you consider stopping therapy versus doxorubicin + dacarbazine/doxorubicin alone versus alternative chemotherapy ?  
2 Answers available
What special considerations do you take when treating cancer patients with severe intellectual disabilities?
Have you been able to deliver standard of care treatment?
1 Answer available
For AML patients, when do you stop antiinfective agents?
At the time of count recovery or do you continue it throughout induction and consolidation?
1 Answer available
Would you treat with AZA + venetoclax to achieve CR2 before proceeding to allogeneic stem cell transplant in a young, fit patient with favorable risk AML who relapsed within a year after 7+3 and HIDAC consolidation?
NGS results are pending
1 Answer available
Do you recommend preloading with IV magnesium to decrease the risk of cisplatin nephrotoxicity?
3 Answers available
What is your practice regarding giving G-CSF to patients with ALL during initial induction?
The patient was recently diagnosed with pre-B ALL and is on day 10 of CALGB 10403. He is expectedly neutropenic as he received daunorubicin and vincri...
2 Answers available
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?
Is completing nodal dissection warranted for surgical management?
1 Answer available
What is your preferred formulation of parenteral iron?
There are various formulations of intravenous iron; each with varying costs, test dose requirement, elemental dose, and number or time of infusions ne...
1 Answer available
Would you extend the duration of anticoagulation in patients with a provoked DVT, but evidence of residual clot at 3 months?
While follow up ultrasound is not usually recommended in provoked DVT, it often is done either for other reasons or by other physicians. Would this in...
3 Answers available
How do you approach and manage anorexia and appetite loss in people with advanced cancer?
How do you counsel patients and caregivers? Do you prescribe medications (''appetite stimulants'') with the goal to improve appetite even if they do n...
4 Answers available
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
2 Answers available
Can CAR T cell therapy be considered for heart transplant recipients with concurrent lymphoproliferative disorders?
1 Answer available
What factors do you use when selecting which NGS platform to use for sequencing solid tumors?
For instance, do you factor availability of RNAseq, inclusion of normal blood controls, and QNS rates into your decision?
1 Answer available
What are your top takeaways from ASH 2023?
7 Answers available
In a patient with recurrent fibrolamellar HCC a year after upfront resection (previously refused adjuvant therapy) with a solitary abdominal mass, would you offer neoadjuvant therapy to assess response?
Or offer resection followed by adjuvant therapy? 
2 Answers available
Do you adjust chemotherapy dose if >=10% change in calculated dose, weight, BSA, or if any of these three parameters are met?
Practice varies among oncologists and institutions
2 Answers available
How soon after CAR T-cell therapy can salvage radiation be delivered?
3 Answers available
How would you approach breast cancer screening in an adolescent patient with a CDH1 mutation?
1 Answer available
What is your approach to cancer patients who inquire about alternative or complementary treatments?
8 Answers available
What is your strategy for breakthrough chemotherapy induced N&V in patients receiving highly emetogenic chemotherapy and already received a NK-1 antagonist, 5-HT3 antagonist, dexamethasone, and olanzapine?
3 Answers available
What is your strategy for managing immunosuppression in patients with a kidney transplant who develop metastatic cancer?
3 Answers available
Is there a concern for the potential of future congenital malformations in offspring when preservation of eggs and sperm is done AFTER cyclophosphamide treatment given that it is an alkylating agent?
1 Answer available
Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?
2 Answers available
What is the ideal period to wait until curative surgery for patients with acute pulmonary embolism and solid malignancy?
Specifically, asymptomatic subsegmental PE diagnosed within a month from planned bilateral mastectomy for breast cancer. 
1 Answer available
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
1 Answer available
How do you manage incidentally identified pituitary lesions on brain imaging?
What workup do you typically recommend?
1 Answer available
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
1 Answer available
How would you treat a stage IIIB recurrent seminoma with early recurrence following first-line treatment with VIP?
2 Answers available
How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?
2 Answers available
What surveillance plan would you recommend for stage IV melanoma patients who achieve a CR or stable PR response with immunotherapy?
1 Answer available
Do you recommend continued PCR testing in a CML patient who underwent allogeneic stem cell transplantation with an identical match about 20 years ago? 
1 Answer available
Would you use a myeloablative or reduced intensity conditioning regiment for a pediatric or AYA patient who does not recover their counts after treatment for AML, but remains disease free?
Would you test for bone marrow failure syndromes before beginning the conditioning regimen?
1 Answer available
How do you approach the management of GVHD prophylaxis in the setting of severe infection?
1 Answer available
How do you approach a patient with newly diagnosed high-grade osteosarcoma who received maximum cumulative dose of doxorubicin for a soft tissue sarcoma 10 years earlier?
2 Answers available
How do you integrate surgery in treatment of recurrent tenosynovial giant cell tumors (TGCT) when using Pexidartinib?
1 Answer available
Do you recommend sperm banking for males prior to undergoing radiation?
Is it necessary to delay the start of radiation therapy for males planning on sperm banking for fertility preservation?
2 Answers available
What surveillance imaging do you obtain for stage III melanoma patients after completing systemic adjuvant therapy?
1 Answer available
How would you adjust the steroid dose for steroid-induced psychosis in a patient being treated for secondary HLH with the HLH-94 protocol?
1 Answer available
What are common indications for ordering NGS of peripheral blood?
Would a negative NGS eliminate the possibility of MDS? Is bone marrow biopsy indicated in a patient with pancytopenia with a negative NGS panel?
1 Answer available
Why do we use dexamethasone for CNS edema and prednisone for pneumonitis?
Is this an artifact of what agent prior clinical trials used or something to do with the mechanism of action (i.e., less mineralocorticoid effect of d...
1 Answer available
How do you approach very treatment-refractory ITP?
Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.
1 Answer available
For patients on immune checkpoint inhibitors presenting with chest pain, dyspnea, fatigue, and troponin elevation, would you recommend early initiation of high dose steroids for empiric treatment of ICI myocarditis while pursuing workup with coronary angiogram, echocardiogram, and/or cardiac MRI, or wait until alternative etiologies have been ruled out?
2 Answers available
How do you manage severe cytarabine syndrome in AML patients, manifesting as severe hypotension, fevers, rash, and myalgias?
Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?
1 Answer available
For patients with incidental findings of venous thromboembolism during workup of a treatable malignancy, how do you approach discontinuation after the treatment is complete?
Would you consider low dose indefinite anticoagulation in any scenario? Any difference in approach between hematological malignancy and solid tum...
1 Answer available
How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?
How is this entity distinct from other secondary HLH entities? 
2 Answers available
What is the role of local control +/- whole lung irradiation in a patient with relapsed/refractory Ewing sarcoma to the hilum plus multiple lung nodules?
Patient initially achieved CR with VAC-IE with resolution of presumed lung mets and 100% necrosis in LLE primary tumor on BKA. Then was NED again afte...
2 Answers available
Would you consider a cycle of EP in a patient with good risk stage IIIB seminoma on BEP but with bleomycin omitted for cycle 3?
Bleomycin omitted due to asymptomatic decline in DLCO
1 Answer available
What are best practices for oncologists during the national platinum shortage?
Please specify how your institution is allocating resources now or will be soon.
13 Answers available
What is your surveillance approach for outpatient monitoring of ICI myocarditis?
(i.e. frequency of serial BNP, troponin, cMRI)
2 Answers available
Given recent studies investigating ICI myocarditis biomarkers such as Temra CD8+ cells, is there now a growing selection of clinical biomarkers, besides BNP and troponin, being measured routinely in ICI myocarditis cases? 
2 Answers available
When would you consider tapering glucocorticoids in a patient with ICI-associated myocarditis?
2 Answers available
Do you routinely recommend loratadine for pegfilgrastim pain?
5 Answers available
How do you mitigate 6-MP-induced GI toxicity in pediatric and AYA patients with leukemia?
2 Answers available
What scenario would prophylactic Tocilizumab be considered to prevent Ipilimumab+Nivolumab (immunotherapy) induced toxicity in malignant melanoma?
1 Answer available
Would you give doxorubicin and cisplatin for localized chondroblastic osteosarcoma in a patient with prior childhood anthracycline exposure and resultant cardiomyopathy with EF 50%?
3 Answers available
What are some alternatives to dexamethasone for brain edema in patients who are allergic, have an intolerance, or refuse the medication?
5 Answers available
Would you use a matched sibling donor with a germline heterozygous BRCA1 mutation for stem cell transplant?
Presuming there are no matched unrelated donors.
1 Answer available
When do you refer AYA patients with newly diagnosed severe aplastic anemia for transplant?
Would you give a trial of IST first or immediately refer for SCT if the patient has matched siblings?
2 Answers available
What is your response to the question, "Is this terminal?"
How do you "have the talk" in a way that is straightforward without emotionally crushing the patient?
8 Answers available
How would you treat an essential-like tremor secondary to tumor (e.g. glioma)?
Is your approach different than that to a primary essential tremor?
1 Answer available
For T cell ALL treated in CR (without transplant), how often do you do BM biopsies as part of surveillance, and for how long?
What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?
1 Answer available
How do you decide between RPLND vs. chemotherapy in patients with Stage IIA mixed germ cell tumor as primary treatment?
3 Answers available
When patients develop headaches from luspatercept, do they tend to improve over time?
1 Answer available
How can oncologists be more collaborative with palliative care physicians?
How can these interactions be improved? 
1 Answer available
Would you consider TPO mimetics for chemotherapy induced thrombocytopenia that persists despite dose reductions?
1 Answer available
How do you clearly communicate to parents that the main purpose of a phase I trial is to find the best dose of a new drug with the fewest side effects rather than treating the patient's cancer?
There is evidence that parents do not adequately understand the purpose of phase I pediatric cancer trials (Cousino et al., PMID 23071225). 
1 Answer available
Do you recommend starting an antiplatelet for primary prophylaxis in post splenectomy thrombocytosis given there is some increased risk of venous thrombosis?
If so, what platelet count threshold would you use? Would age impact your decision? Would you do a bone marrow to rule out primary MPD in adults if th...
1 Answer available
What is the optimal age at which a patient with sickle cell disease should undergo allogeneic stem cell transplant?
2 Answers available
Would you recommend adding a TKI to a pediatric regimen for a AYA B-ALL patient with IKZF1 mutation?
1 Answer available
Should high-dose methotrexate be used in the treatment of AYA patients with osteosarcoma?
2 Answers available
How would you approach a sarcoma that was initially diagnosed as UPS of the distal femur with groin lymph node spread, resected, and found to have an EWSR1-FLI1 fusion diagnostic of Ewing's on NGS?
1 Answer available
What is your treatment approach for a pediatric patient with uterine embryonal rhabdomyosarcoma found after removal of a prolapsing uterine mass, with no evidence of distant metastasis on imaging?
1 Answer available
In a patient with HR B ALL and severe pancreatitis due to peg-asparaginase, how do you assess the impact of peg discontinuation on risk of relapse?
For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?
2 Answers available
Do you switch from imatinib to another TKI in patients with chronic phase CML who develop renal insufficiency?
There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?
2 Answers available
When treating patients with immune checkpoint inhibitors, do you routinely check markers of endocrinopathies such as TSH/ACTH, or only when a patient has symptoms?
If so, how often do you check these labs?
1 Answer available
What are your top takeaways from ASH 2022?
8 Answers available
How do you approach hormone replacement therapy for premenopausal patients following pelvic radiation therapy?
How is your approach different from or similar to those who undergo surgical menopause? 
1 Answer available
Do you do prophylactic LP/IT chemotherapy in high risk APML prior to starting consolidation?
1 Answer available
How would you work up a mildly neutropenic patient (ANC >800) with family history of neutropenia and personal history of occasional mouth sore?
What are indications to order gene mutation studies (e.g. ELANE) and how would it help the patient?
1 Answer available
What chemotherapy regimen would you use for a testicular cancer patient in need of BEPx3 but unable to use platinum based chemotherapy regimen due to cochlear implants?
2 Answers available
How do you manage prophylactic antimicrobial medications in patients who undergo ATG/cyclosporine/eltrombopag induction for severe aplastic anemia?
What would you recommend within the first year after ATG and thereafter if still maintained on cyclosporine?
1 Answer available
What is your approach to BK hemorrhagic cystitis not responding to cidofovir?
1 Answer available
Which patients with acute promyelocytic leukemia do you consider maintenance after completing consolidation?
1 Answer available
How do you discern whether elevated liver enzymes are from immunotherapy versus chemotherapy when a patient is on combination chemo/immunotherapy?
2 Answers available
What would your next line treatment be for a patient previously treated with repeat resection, craniospinal irradiation, and initial cisplatin/vincristine/CCNU with medulloblastoma?
What would be your next treatment for a young adult patient with medulloblastoma refractory to repeat resection, craniospinal irradiation, and initial...
1 Answer available
Which chemo regimen, if any, would you use as adjuvant treatment in a young patient with primary malignant thyroid teratoma?
Would surgical margins, evidence of angiolymphatic spread, number of lymph nodes removed during surgery inform your decision? 
1 Answer available
Should post-transplant cyclophosphamide be utilized for all matched unrelated donor peripheral blood stem cell transplants for hematologic malignancy?
If not, how do you choose GVHD prophylaxis regimen? Is there a preference?
2 Answers available
What is your approach to adjuvant treatment for stage IA small cell carcinoma of the ovary, hypercalcemic type, after fertility sparing surgical staging?
1 Answer available
How would you approach cytopenias 5 weeks after initial dosing in a young patient with MDS treated with Azacitadine as a bridge to transplant?
E.g. would you dose-reduce or continue at same dose? Baseline ANC was in the normal range
1 Answer available
When do you refer patients for germline testing when somatic tumor testing is negative for actionable mutations?
How reliable is somatic testing to detect an underlying germline predisposition?
2 Answers available
Is cross reactivity low enough to try cisplatin as an alternative for patients who experience hypersensitivity reaction to carboplatin?
Is skin testing advised prior to trialing alternative?
2 Answers available
How would you approach an early stage II unfavorable Hodgkins lymphoma following 6 cycles ABVD with persistent Deauville 5 with negative biopsy?
iPET2 and iPET4 showed Deauville 5 response. CT biopsy after 4 cycles was negative. Patient is currently scheduled for 2 additional cycles of ABVD.
1 Answer available
How would you treat a locally-recurrent extraosseous (pulmonary) Ewing sarcoma?
Ewing sarcoma of the right lung, status post bi-lobectomy and adjuvant VDC/IE, with recurrence 6 years in the right lung only. He has reached a cumula...
1 Answer available
What is your approach in a fit patient, advanced stage, bulky classical Hodgkin lymphoma who has decreased disease burden in areas but a persistent, hypermetabolic (Deauville 5) anterior mediastinal mass following two cycles of AAVD?
2 Answers available
What are your recommendations for a male patient who was recently started on imatinib and wants to conceive?
4 Answers available
What is your institutional approach to a restrictive “neutropenic diet”?
3 Answers available
How would you work up and manage persistent lymphopenia in an asymptomatic patient?
ALC<200
1 Answer available
What is the benefit of cytoreduction with Hydroxyurea for patients with newly diagnosed chronic phase CML with a WBC count >100 prior to the initiation of a TKI?
1 Answer available
How do you manage AEDs in patients with malignant brain tumors?
Do you ever add prophylactic Keppra (levetiracetam) for glioblastoma patients without a seizure history based on data such as this study (nature.com) ...
5 Answers available
What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?
1 Answer available
How do you manage a patient with a history of high-risk leukemia who has increasing loss of donor chimerism in the post-transplant setting in the absence of disease relapse?
How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...
1 Answer available
At what platelet count would you feel comfortable dosing aspirin 81 mg for coronary artery disease in a patient with ITP?
Presuming strong indication for ASA - eg history of NSTEMI
1 Answer available
How has the virtual aspect of tumor boards impacted their educational quality in the Covid-19 era?
1 Answer available
Is there any benefit to transplant patients with Ph+ ALL who have achieved MRD-negativity?
1 Answer available
How do you manage insomnia in cancer patients that is refractory to traditional sleep aides?
In patients who continue to have insomnia despite diphenhydramine, benzos, and trazodone, are there other evidence based treatments that are helpful?
4 Answers available
How do you manage real-time release of pathology and radiology results to oncology patients following enaction of the CURES act?
1 Answer available
Do you routinely offer antiviral prophylaxis for patients receiving chemoimmunotherapy?
If so, what regimen do you utilize?
1 Answer available
In a patient with stage 1 mixed germ cell tumor who cleared tumor markers post-orchiectomy but with subsequent rise to borderline abnormal within 6 weeks, would you treat with 3 cycles BEP as for S1 disease?
If serum markers were normal, how strongly do you consider 1 cycle of BEP for embryonal predominant pathology? 
1 Answer available
How do you manage patients with chemotherapy-induced paronychia?
1 Answer available
For a young male with Stage III intermediate risk NSGCT with active 1 ppd smoking history but normal PFTs and DLCO results, would you still consider use of BEP x 4?
VIP can be considered, but given complex psychosocial issues and limited community cancer treatment resources, this question is being asked. 
2 Answers available
Are there best practices or data regarding the use of open notes among oncology patients?
What is the impact among patients and providers? Has your documentation been adjusted now that patients can readily review?
2 Answers available
How do you approach heparin management in patients who have suprathetherapeutic Xa levels on minimal heparin?
1 Answer available
Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?
1 Answer available
Do you routinely check Pulmonary function testing prior to each cycle of BEP for young patients with testicular cancer with no pulmonary risk factors?
NCCN guidelines state check at baseline and then as clinically indicated. Some other sources state, can check prior to each cycle of BEP?  What ...
2 Answers available
How do you incorporate denosumab into the surgical management of giant cell tumor of bone?
Does the degree of resectability affect your management?
2 Answers available
Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?
Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?
1 Answer available
How do you manage drug-induced thrombocytopenia when the implicated drug is essential?
e.g. DITP from eptifibatide after a cardiac intervention
1 Answer available
For treatment of ITP, what would you add to dexamethasone to achieve the fastest recovery in a patient waiting for a procedure?
IVIG, TPO, or other agents?
1 Answer available
How do you approach therapy for a patient with stage IIIA NSGCT who received 4 cycles of EP followed by RPLND which revealed residual mixed teratoma and embryonal carcinoma?
Given persistent embryonal histology on RPLND, do you favor observation or TIP/VIP? What do you use to guide your decision?
1 Answer available
What features help distinguish thyroid myopathy from immune checkpoint inhibitor-associated myopathy?
1 Answer available
Would you change chemotherapy to VIP in a young patient with stage IIIB intermediate risk non-seminomatous germ cell tumor with borderline DLCO after one cycle of BEP?
2 Answers available
How would you treat a young patient with classical intermediate-risk Hodgkin lymphoma who has an underlying DNA repair-deficiency disorder, such as congenital mismatch repair disorder or ataxia telangiectasia?
How does your treatment approach vary depending on the underlying predisposition?
1 Answer available
How do you approach relapsed idiopathic HLH?
2 Answers available
What are contraindications for growth factors in patients with hematologic malignancies?
2 Answers available
Do you routinely check platelet counts after COVID-19 vaccines in patients with chronic ITP?
1 Answer available
How do you manage a patient with superficial venous thrombosis with close proximity (<3 cm) to deep veins and an inherited thrombophilia ?
Would you offer indefinite anticoagulation if the event is unprovoked and the patient has low bleeding risk? 
1 Answer available
Is there experience/reports of using voxelotor in sickle cell patients who are Jehovah Witnesses with few crises but who have fatigue and/or dyspnea?
Also is there value in using voxelotor for the purpose of reducing hemolysis, and if so what parameters do you use to determine when to initiate voxel...
1 Answer available
What is your preferred approach for patients with anti-phospholipid syndrome with recurrent thrombosis on coumadin and LMWH?
1 Answer available
How would you approach moderate neutropenia (ANC < 1000) in a solid organ transplant recipient?
Is there a particular sequence you would adjust contributing antirejection or antimicrobial medications? Is the use of G-CSF appropriate and at what c...
2 Answers available
What is the role of hydroxyurea in variant sickle cell genotypes?
Hydroxyurea is demonstrated to reduce complications and improve long-term outcomes in severe genotypes HbSS and sickle beta0 thalassemia. What clinica...
2 Answers available
In what circumstances would you give G-CSF to a patient with severe neutropenia and HLH?
1 Answer available
How do you approach conversations regarding discontinuation of transfusions in patients with advanced hematologic malignancies who are otherwise appropriate for hospice?
Are there other supportive care interventions that would otherwise be covered by hospice?
1 Answer available
How would you manage VTE in a patient with bleeding disorder such as hemophilia?
Have you used anticoagulants other than coumadin? Or is that the only appropriate agent given monitoring is based on PT/INR?
1 Answer available
How long should patients treated with frontline therapy for Hodgkin lymphoma wait before attempting to conceive a child?
Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...
1 Answer available
What regimen would you offer a young patient with T-cell ALL who recurred a short time after allo-transplant and was initially treated with CALGB10403?
Especially with the current drug shortage of nelarabine.
2 Answers available
Would you start TKI therapy in a patient with new diagnosis of T-ALL without BCR-ABL gene rearrangement on FISH but found to have very low level p190 transcript on RT-PCR?
1 Answer available
How do you approach management of sickle cell patients who mistrust Western medicine and prefer naturopathic therapies?
While building a trusting patient-physician relationship, what therapies could be discussed that may be aligned with naturopathic medicine? (i.e. L-gl...
1 Answer available
How would you manage asymptomatic brain metastases from testicular non-seminomatous germ cell tumor with a choriocarcinomatous component?
2 Answers available
In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?
2 Answers available
How do you approach treatment of a glioblastoma in pregnancy?
3 Answers available
Do you use premedications (acetaminophen, diphenhydramine) before pRBC and plt transfusions to prevent febrile nonhemolytic transfusion reactions and allergic reactions?
Does manipulation of blood products (leukoreduction, irradiated) affect your approach? There is growing evidence that routine premedication (at least ...
1 Answer available
What is the utility of immunotherapy in management of malignant peripheral nerve sheath tumors?
In particular, is there any data on the efficacy of Ipilimumab/Nivolumab?
1 Answer available
Under what circumstances would you consider anticoagulation in a young female patient with persistently elevated factor XI activity?
While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...
1 Answer available
How would you optimally manage a patient with a MDS/MPN overlap syndrome who has both transfusion-dependent anemia and marked thrombocytosis?
Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)? Would this change with someone who is more fit vs more frail?
1 Answer available
Do you think there is any compelling data to support giving brentuximab as frontline therapy for pediatric patients with Hodgkin lymphoma?
Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients  
1 Answer available
How would you approach immunosuppression for patients with severe aplastic anemia who are not transplant or ATG candidates?
Such as patients who are frail, elderly, renally impaired? Would you consider sirolimus over cyclosporine or tacrolimus for safer nephrotoxicity prof...
1 Answer available
How long do you continue caplacizumab in relapsed refractory TTP?
How often do you monitor ADAMTS-13 levels off therapy?
1 Answer available
Are there any reasons to consider a prolonged course of steroids with taper over a shorter course of pulsed steroids in the treatment of ITP?
For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?
1 Answer available
What strategies have you found to be most effective in engaging PCPs in a primary-care or shared-care model of survivorship for pediatric and AYA patients who will receive ongoing care in their communities away from their primary oncology treatment site?
In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients. 
1 Answer available
With new data showing similar outcomes of mismatched unrelated donor and haploidentical related donor allogeneic transplants using post transplant cyclophosphamide, how does one decide which donor is optimal?
If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...
1 Answer available
How is pediatric and young adult primary bone lymphoma risk stratified?
NCCN guideline V4.2021 DLBCL page BCEL-3 states stage I-II, bulky >= 7.5cm should be treated with 6 cycles of RCHOP, but most bone lymphoma studies...
1 Answer available
Would you consider bone marrow transplant in a pediatric patient with recurrent HLH with no identified exogenous trigger or HLH-associated mutation?
0 Answers available
How would you approach chronic isolated severe non-cyclic neutropenia with negative bone marrow and rheumatologic work-up?
Is there a role for empiric antibiotics if there is history of opportunistic infection?
1 Answer available
How do you manage cancer treatment-related cognitive change or "chemo brain?"
Are there any effective non-pharm or pharm interventions?
1 Answer available
What dose of PEG-asparaginase do you recommend for teens with high BMI treated on a pediatric ALL regimen?
Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...
2 Answers available
How would you treat an advanced stage small-cell carcinoma of the ovary, hypercalcemic type? (SCCOHT)?
s/p optimal debulking. If this was an early-stage cancer would it change your adjuvant therapy recommendations?
1 Answer available
What treatment regimen would you recommend for young adults with platinum refractory relapsed germ cell tumors?
2 Answers available
How do you approach the use of low-dose aspirin for primary prevention in non-pregnant patients with SLE and positive aPL antibodies, without clinical criteria for APS?
Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?
1 Answer available
Should targeted therapies such as Brentuximab or Crizotinib be used in the upfront management of anaplastic large cell lymphoma in a pediatric or AYA patient?
1 Answer available
What is the role of targeted therapy in relapsed/refractory ALK+ anaplastic large cell lymphoma?
Would you use ALK inhibitors such as crizotinib based on recent phase II data? Are there any research efforts to combine ALK inhibitors with current ...
1 Answer available
What is the preferred treatment approach for an AYA patient with intermediate to high risk Hodgkin lymphoma: The pediatric approach (ABVE-PC +/- radiation) or the adult approach (ABVD with possible escalation to BEACOPP)?
1 Answer available
When can defibrotide be discontinued before the 21-day treatment course is completed in a pediatric patient with SOS?
Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?
1 Answer available
How do you choose your systemic treatment for primary mediastinal grey zone lymphomas?
Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?
3 Answers available
Should patients receive thrombophilia testing in the setting of a provoked VTE secondary to hormonal therapy/OCPs?
While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?
2 Answers available
Can an AYA patient with newly diagnosed AML safely sperm bank after starting cytoreduction with hydroxyurea or cytarabine?
2 Answers available
Would you offer immunotherapy for recurrent metastatic Ewing sarcoma if the tumor is MSI high or has high TMB?
1 Answer available
What are the current official guidelines regarding COVID-19 vaccination for patients with cancer or for hematologic conditions?
2 Answers available
Is a patient with secondary myeloid sarcoma a candidate for hematopoietic stem cell transplant?
2 Answers available
How would you time COVID-19 vaccination with someone on R-CHOP chemotherapy?
1 Answer available
How do you determine when to give a second CAR-T cell infusion to a pediatric or young adult patient with relapsed/refractory ALL?
2 Answers available
How would you approach the treatment of patients with von Willebrand disease or hemophilia A previously managed with intranasal DDAVP during the recall?
During the Stimate recall, how are we performing DDAVP challenges for newly diagnosed hemophilia A or von Willebrand disease?
1 Answer available
For AYA patients with early-stage Hodgkin's lymphoma being treated with ABVD, how many cycles of chemotherapy do you administer, and when can radiation be avoided?
Have the RAPID or CALGB 5064 studies changed your treatment approach?
2 Answers available
How do you counsel patients who are candidates for a clinical trial regarding their options?
Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?
2 Answers available
When should a gallium-dotatate scan be incorporated into the initial evaluation of a patient with a carcinoid tumor of the appendix?
1 Answer available
What are your thoughts on adding mycophenolate to steroids in the first line treatment of ITP based on the results of the FLIGHT trial?
Presented at ASH: FLIGHT trial
1 Answer available
How would you treat an adolescent or young adult with newly diagnosed hepatosplenic T-cell lymphoma?
1 Answer available
How do you approach a patient with multiply relapsed germ cell tumor with rising tumor markers but no obvious site of disease?
If standard of care BEP chemo, tandem transplant, and radiation to primary site have been done previously.
1 Answer available
For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?
1 Answer available
Do hemoglobin S levels always correlate with SCD phenotype?
What is the lowest level you have seen with uncomplicated or complicated crises?
4 Answers available
Do you re-test patients who test positive for COVID-19 during or prior to starting cancer treatment?
There are mixed recommendations about re-testing vs simply waiting for a quarantine period prior to resuming therapy. 
2 Answers available
How do you manage a young patient with mediastinal nonseminomatous germ cell tumor that has relapsed after primary treatment with four cycles of VIP?
1 Answer available
How do you manage VTE in the setting of persistent severe thrombocytopenia?
Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?
3 Answers available
Is there any role for direct oral anticoagulants in the treatment of antiphospholipid syndrome?
What if this was "triple-negative" antiphospholipid syndrome?
2 Answers available
At what level of bone marrow disease would you agree to proceed with transplant for a patient with refractory AML?
I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?
1 Answer available
How do you approach the pharmacologic management of cancer-related fatigue?
After optimizing symptoms and reversible factors, and attempting cognitive-behavioral interventions and exercise, do you recommend pharmacologic agent...
2 Answers available
How would you approach therapy for a young, fit patient with alveolar rhabdomyosarcoma involving the anterior nasal vault/sinuses in the absence of available clinical trials?
Presented with mass projecting into right/left anterior ethmoid complex
1 Answer available
How would you treat a young patient with symptomatic Rosai-Dorfman disease who has recurrent, life-threatening pericardial and pleural effusions?
CT scans show omental and pelvic disease.
1 Answer available
How would you approach treatment in an otherwise young, fit patient with transformed AML currently in remission with a plan for transplant and was found to have an invasive fungal infection not amenable to resection upon recovery from induction?
Would you consider “bridging” therapy with something like an HMA?
1 Answer available
How would you approach langerhans cell histiocytosis involving a single bone site after resection?
1 Answer available
During induction therapy for acute leukemia, when do you decide to discontinue the antimicrobial prophylaxis?
Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?
1 Answer available
What are the options of induction treatment of young AML patients who are on CRRT, continuous renal replacement therapy ?
1 Answer available
For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?
Does acute leukemia sub-type affect your decision? 
1 Answer available
How do you choose first or second-line systemic therapy for fibrolamellar hepatocellular carcinoma?
What are there most evidence-based options?
1 Answer available
How do you approach the decision of whether and when to initiate therapy in patients who remain COVID-19 positive >2 weeks after infection but are asymptomatic from the virus?
E.g. a patient with progression of their primary cancer but still is testing COVID19+ over a month after infection?
5 Answers available
When during ALL induction therapy are you checking for MRD?
1 Answer available
Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?
Are you placing more weight on patient risk factors such as age >65 or co-morbidities?
2 Answers available
How do you counsel patients and caregivers regarding management of cancer-associated cachexia?
What advice do you give regarding dietary practices, feeding tubes / parenteral nutrition, and pharmacotherapy specifically for cachexia?
1 Answer available
Is there a Mednet app?
2 Answers available
What is your approach to unresectable metastatic rhabdomyosarcoma transformed from an embryonal cell germ cell tumor?
Should treatment be based on current histology (rhabdomyosarcoma) or origin (germ cell)?
1 Answer available
Would you hold rituximab for newly diagnosed B-cell lymphoma if the patient is COVID-19 positive?
What if the patient has a history of confirmed COVID-19 but has since recovered?
1 Answer available
What treatment would you offer a young pregnant woman with a symptomatic midline low grade glioma?
Discussion of treatment options for midline low-grade glioma causing life-altering symptoms in a pregnant patient to avoid teratogenicity.
2 Answers available
How do you determine whether to treat a young adult with stage IA Hodgkin Lymphoma with the adult or pediatric treatment paradigm?
At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...
2 Answers available
Do you offer fertility preservation to patients prior to CAR-T therapy?
Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?
1 Answer available
How do you treat a patient with a history of clinical stage IIb cN2, mixed germ cell embryonal carcinoma treated with BEP and RPLND five years ago, who now has signet ring cell adenocarcinoma with abdominal carcinomatosis with an unknown primary?
GI work up negative. NGS cancer type and isochromosome 12p ordered and pending. Pathology at RPLND was negative for cancer.  
3 Answers available
In what situations do you utilize G-CSF in germ cell tumors or Hodgkin lymphoma patients receiving bleomycin?
There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.
2 Answers available
How do you decide the right time to transition to hospice?
Obviously, patient and caregiver preferences are paramount. But, what factors do you consider? Does expanded hospice (e.g., Medicare Care Choices) inf...
4 Answers available
What chemotherapy would you recommend for a patient with Ewing Sarcoma who has relapsed after being initially treated with vincristine/doxorubicin/ifosfamide?
2 Answers available
Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?
2 Answers available
How should you manage a COVID-19 infected/suspected patient who is receiving chemotherapy and cannot interrupt or delay their cancer treatment?
2 Answers available
In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?
Acknowledging that there is no time for good trials yet in this setting
1 Answer available
How should you manage a coronavirus infected/suspected patient who is receiving radiotherapy and cannot interrupt or delay their cancer treatment?
How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...
7 Answers available
Should I wear gloves during a routine physical exam on an asymptomatic patient with no risk factors for COVID-19?
1 Answer available
Is there any consensus or guidance on how to manage germ cell tumor patients in the COVID-19 era?
1 Answer available
How does the management of nasopharyngeal cancer in kids/young adults differ from adult patients?
-The data on induction for adult H&N ca has been mixed (excluded NPX) but recent data suggest a benefit for adult NPX. -Given that this is standa...
1 Answer available
Do you routinely use tumor lysis prophylaxis when starting chemotherapy for germ cell tumors?
How do you assess risk of tumor lysis syndrome, and is hydration sufficient or should hypouricemic agents be used as well?
2 Answers available
Is it unusual to have isolated LDH elevation and normal HCG and AFP in non-seminomatous germ cell tumor (embryonal carcinoma)?
In a patient s/p orchiectomy and with pelvic lymphadenopathy, would you consider lymph node biopsy to confirm involvement by non-seminomatous germ cel...
2 Answers available
What is the standard of care (if any) for pediatric desmoplastic round cell tumor?
Is there a role for immunotherapy outside of trial setting?
1 Answer available
How do you present the trade off between a small chance of a sustained response for a new drug at the expense of potential worsening quality of life?
1 Answer available
How do you manage a patient with a history of non-seminomatous germ cell tumor who has a rising AFP after primary chemotherapy without any imaging evidence of recurrence?
Given the non-specific nature of AFP and its elevation in various benign conditions, is there an AFP cutoff level or change over time for which you wo...
1 Answer available
For high risk, stage I, non-seminomatous testicular germ cell tumors, are there particular circumstances under which RPLND is clearly preferred over chemotherapy or surveillance?
Is any amount of teratoma or PNET an indication for surgery?
1 Answer available
When would you consider testicular RT prior to TBI for BMT?
What dose do you recommend?
1 Answer available


Papers discussed in this category

Gynecol Oncol, 2019 Aug 16
Advanced communication: A critical component of high quality gynecologic cancer care: A Society of Gynecologic Oncology evidence based review and guide.
JAMA,
The care of the patient.
Cancer, 2004-08-15
The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation.
Br. J. Haematol., 2003-11-01
Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia.
Br. J. Haematol., 1998-08-01
Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.
Cancer, 1990-11-15
Testicular relapse in children with acute nonlymphoblastic leukemia.
Radiother Oncol, 1990-01-01
Total body irradiation for bone marrow transplantation: the Memorial Sloan-Kettering Cancer Center experience.
Indian J Urol,
Severe acute tumor lysis syndrome in patients with germ-cell tumors.
Medical and pediatric oncology, 1981
The cytosine arabinoside (Ara-C) syndrome.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016-07
Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.
Clinical breast cancer, 2003-02
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Clin. Cancer Res.,
Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival.
Fertil. Steril., 2013 Sep 05
Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.
The New England journal of medicine, 2020 Apr 22
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
J. Clin. Oncol., 2019 Sep 25
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Lancet Oncol., 2020 Feb 14
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
Ann. Oncol., 2020 Mar 26
Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China.
Chest, 1997-03
Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
J. Clin. Oncol.,
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Clin Genitourin Cancer, 2017 Sep 04
Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.
Eur. Urol., 2020 Jan 01
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
J. Clin. Oncol., 2019 Sep 10
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Journal of the National Cancer Institute, 2005-09-21
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
Eur. J. Cancer,
Incidence of second primary cancer following testicular cancer.
Br. J. Cancer, 2007 Jan 30
Mortality and incidence of second cancers following treatment for testicular cancer.
American journal of hematology, 2018-08
Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Blood, 2019-04-04
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Am. J. Hematol., 2019 Nov 19
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
J. Neurosurg., 2017 Mar 03
Interactions between glioma and pregnancy: insight from a 52-case multicenter series.
Acta Neurochir (Wien), 2019 Jan 29
Influence of pregnancy on glioma patients.
J. Neurooncol., 2018 Apr 06
Clinical challenges of glioma and pregnancy: a systematic review.
J. Clin. Oncol., 2020 May 20
Management of Cancer Cachexia: ASCO Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-10
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03
Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.
Oncologist, 2020 Mar 10
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Semin Diagn Pathol, 2016 Dec 23
Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
The New England journal of medicine, 2007-01-25
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Haematologica, 2020
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.
Nature, 2019-03
Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Blood, 2018 May 02
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.
Leuk Lymphoma, 2019 Dec 26
Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.
Journal of the National Cancer Institute, 2013-08-21
Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010-02
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).
Blood, 2018 Jul 12
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Ann. Intern. Med., 2019 Oct 15
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Blood Transfus, 2018 Oct 24
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.
J Thromb Haemost, 2018 May 08
Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.
Blood, 2015-10-29
Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection.
The New England journal of medicine, 2017-02-02
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Blood, 2009 Nov 10
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-03-15
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
Clin Nutr, 2015 Aug 28
The association of substituting carbohydrates with total fat and different types of fatty acids with mortality and weight change among diabetes patients.
Clin Lymphoma Myeloma Leuk, 2017 Mar 07
Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.
American journal of hematology, 2011-10
Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia.
The American journal of medicine, 2017-12
Results of the First American Prospective Study of Intravenous Iron in Oral Iron-Intolerant Iron-Deficient Gravidas.
American journal of hematology, 2018-05
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
Am J Hematol, 2020 Jun 29
A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial.
Am J Hematol, 2019 Sep
A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
Am J Hematol, 2019 Sep
Single total dose infusion of ferumoxytol (1020 mg in 30 minutes) is an improved method of administration of intravenous iron.
Am J Hematol, 2018 Jun
Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia.
JAMA,
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
N Engl J Med,
Sickle Cell Disease.
The journal of allergy and clinical immunology. In practice, 2017
Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.
Archives of surgery (Chicago, Ill. : 1960), 2008-07
Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018-01
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
Ann Surg,
Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE).
N. Engl. J. Med., 2015-04-23
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
Blood, 2018 Sep 6
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
J Clin Oncol, 2017 Mar 14
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
Blood, 2020 Sep 23
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.
The Lancet. Oncology, 2018-03
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
The Lancet. Oncology, 2019-06
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
J Hematol Oncol, 2016 Jun 03
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.
The Lancet. Oncology, 2017-11
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Blood, 2013-12-05
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.
Blood Adv,
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
Blood,
Five hematologic tests and treatments to question.
Blood, 2020 Jan 30
Long-term treatment of venous thromboembolism.
Blood, 2013 Sep 19
Management of the refractory aplastic anemia patient: what are the options?
The Lancet. Haematology, 2015-09
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.
Haematologica, 2017-07
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia.
Thrombosis, 2013
A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis.
Thrombosis journal, 2023 Oct 26
The clinical application of venous ultrasound in diagnosis and follow-up of lower extremity deep vein thrombosis (DVT): a case-based discussion.
American journal of hematology, 2019-04
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Cancer medicine, 2019-01
Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
Journal of the National Cancer Institute, 1988-07-06
The role of methotrexate in osteosarcoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Anticancer Drugs,
Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma.
J Adolesc Young Adult Oncol, 2019 Nov 08
Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.
N. Engl. J. Med., 2018-01-25
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Bone Marrow Transplant, 2019 Oct 01
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.
Front Immunol, 2020 Apr 03
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation.
Blood, 2021 Mar 08
Brentuximab Vedotin in Combination with Chemotherapy for Pediatric Patients with ALK+ALCL: Results of COG Trial ANHL12P1.
Gynecologic oncology, 2016-01
Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
Gynecol Oncol, 2020 Jul 9
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
Gynecol Oncol, 2020 Jul 25
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
The New England journal of medicine, 2016-07-14
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Practical radiation oncology, 2021 Sep-Oct
Medical Marijuana for Cancer: Perspective From a Radiation Oncologist Credentialed to Certify in Pennsylvania.
Palliative medicine, 2022 Mar 31
Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: A systematic review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Mar 28
Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
J Clin Oncol, 2021 Apr 07
Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
Ann Oncol, 2007 Nov 15
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Leuk Lymphoma, 2019 Nov 04
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Seminars in hematology, 2013-07
Evaluation and management of patients with isolated neutropenia.
EMBO Mol Med, 2020 Apr 29
Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases.
J Oncol, 2020 Jun 24
Pathogenesis, Assessments, and Management of Chemotherapy-Related Cognitive Impairment (CRCI): An Updated Literature Review.
Pediatr Blood Cancer, 2019 Jul 24
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).
J. Clin. Oncol., 2020 Feb 14
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Cancer, 2020 May 19
Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-01
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.
Cancer, 2020 Mar 15
High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases.
J Clin Oncol, 2021 Apr 06
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Ann Oncol, 2021 Mar 18
Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.
Clin Transl Oncol, 2020 Sep 17
ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.
J Assist Reprod Genet, 2020 Jun 02
Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
Lancet Oncol, 2018 Sep 13
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-02-20
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
Lancet (London, England), 2010-12-11
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Blood, 2012 Apr 04
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
Clin Lymphoma Myeloma Leuk, 2019 Sep 30
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Bone Marrow Transplant, 2018 Jun 08
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
The Lancet. Oncology, 2017-09
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
J Clin Oncol, 2020 Apr 10
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Blood, 2016-07-14
How I treat patients with inherited bleeding disorders who need anticoagulant therapy.
Blood, 2016 Sep 26
New concepts for anticoagulant therapy in persons with hemophilia.
Transfusion, 2020 Sep 24
Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
Lancet Haematol,
Management of anticoagulant-refractory thrombotic antiphospholipid syndrome.
British journal of haematology, 2014-06
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
International journal of radiation oncology, biology, physics, 2019-06-01
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Blood, 2018-07-05
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood,
Getting to transplant in Hodgkin lymphoma: BVB.
Blood,
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
J Clin Oncol, 2021 Jun 25
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Journal of the National Cancer Institute, 2010-08-18
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Blood, 2019-06-06
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
Eur J Haematol, 2021 Feb 17
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011-10
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
Journal of oncology practice, 2019-01
Putting Integrative Oncology Into Practice: Concepts and Approaches.
Support Care Cancer, 2021 Aug 16
MASCC antiemetics in advanced cancer updated guideline.
Arthritis Rheumatol, 2021 Apr 01
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
The New England journal of medicine, 1981-09-24
The role of maintenance therapy in disseminated testicular cancer.
Ann Intern Med,
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.
Cancer, 2011 Feb 01
Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial.
Cancer Cell, 2020 Oct 08
Open Notes in Oncology: Patient versus Oncology Clinician Views.
J Gen Intern Med, 2021 Feb 02
Words Matter: What Do Patients Find Judgmental or Offensive in Outpatient Notes?
JAMA Netw Open, 2020 Jun 01
Frequency and Types of Patient-Reported Errors in Electronic Health Record Ambulatory Care Notes.
Practical radiation oncology, 2019-03
Impact of Open Access to Physician Notes on Radiation Oncology Patients: Results from an Exploratory Survey.
Blood, 2008-02-15
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Blood, 2016-07-28
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Blood advances, 2016-12-27
US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.
The Lancet. Haematology, 2018-12
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
N Engl J Med,
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-04
Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Pediatr Blood Cancer, 2019 Jul 31
Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia.
American journal of hematology, 2020 Dec 08
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
Blood cancer journal, 2023 Oct 11
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
Journal of hospital medicine, 2018-08-01
Things We Do For No Reason: Neutropenic Diet.
Front Oncol, 2022 Mar 09
Neutropenic Diet Cannot Reduce the Risk of Infection and Mortality in Oncology Patients With Neutropenia.
BMJ Support Palliat Care, 2022 Jul 08
Neutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial.
Nutr Cancer, 2019 Oct 12
Lack of Efficacy of the Neutropenic Diet in Decreasing Infections among Cancer Patients: A Systematic Review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-01
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Sci Rep, 2020 Jul 01
Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy.
Neuro Oncol,
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.
Gastroenterology, 1993-06
Hepatoprotective properties of ursodeoxycholic acid.
Gastroenterology, 1991 Jul
Evidence for a direct hepatoprotective action of ursodeoxycholic acid in primary human hepatocytes.
Z Naturforsch C J Biosci, 2002 Mar-Apr
Prophylactic effect of aqueous propolis extract against acute experimental hepatotoxicity in vivo.
Immunopharmacol Immunotoxicol, 2003 Nov
Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice.
Exp Toxicol Pathol, 2002 Feb
Acetaminophen hepatotoxicity and mechanisms of its protection by N-acetylcysteine: a study of Hep3B cells.
Biochem Biophys Res Commun, 1999 Sep 24
Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants.
Ital J Gastroenterol Hepatol, 1998 Dec
Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients.
Chem Biol Interact, 2001 Dec 21
Vitamin E succinate protects hepatocytes against the toxic effect of reactive oxygen species generated at mitochondrial complexes I and III by alkylating agents.
Metal-based drugs, 2010
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.
J Allergy Clin Immunol Pract, 2019 Feb 15
Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.
Pediatr Blood Cancer, 2021 Apr 12
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
The Lancet. Haematology, 2019-03
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
J Clin Oncol, 2021 Dec 02
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
Urology, 1982-09
Prevention of cyclophosphamide-induced hemorrhagic cystitis.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-03
Intravesicular cidofovir for the management of BK virus-associated cystitis.
Clin Infect Dis, 2005 Jan 21
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Pediatr Transplant, 2014 Sep 08
Successful treatment of hemorrhagic cystitis after hematopoietic stem cell transplantation with intravesical hyaluronic acid.
J Clin Oncol, 2021 Apr 30
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.
Pediatr Infect Dis J, 2014 Nov
Effective treatment of severe BK virus-associated hemorrhagic cystitis with leflunomide in children after hematopoietic stem cell transplantation: a pilot study.
Bone Marrow Transplant, 2006 Mar
Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2008-01-15
Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity.
Eur J Clin Pharmacol, 2001 Aug
Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
JAMA Netw Open, 2021 Aug 02
Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis.
Blood, 2006-05-01
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-02-01
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Blood, 2017-03-09
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
The Lancet. Oncology, 2015-10
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
N Engl J Med, 2013 Jul 11
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Blood, 2012 Jun 19
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Genetic epidemiology, 2016-09
Association Between Absolute Neutrophil Count and Variation at TCIRG1: The NHLBI Exome Sequencing Project.
American journal of hematology, 2019-03
Neutropenia in the age of genetic testing: Advances and challenges.
Blood, 2021 Jan 07
When non-Whiteness becomes a condition.
Blood, 2019-04-11
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
N Engl J Med, 2022 Dec 11
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
European journal of cancer (Oxford, England : 1990), 2017-04
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-02-01
Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.
Obstet Gynecol, 1998 Oct
Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee.
Acta Oncol, 2019 Apr 08
Sex steroid hormone receptor expression in the vaginal wall in cervical cancer survivors after radiotherapy.
Journal of neurosurgery, 2013-04
A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.
Cochrane Database Syst Rev, 2020 Apr 28
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
J Clin Pharmacol, 2021 Jul 16
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Eur Heart J, 2022 Nov 01
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
JACC CardioOncol, 2022 Dec 20
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions.
Pediatric blood & cancer, 2018-02
Consensus and controversies regarding the treatment of rhabdomyosarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-01
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Blood, 2018 Apr 5
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood Adv, 2021 Aug 24
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Blood, 2014 Apr 16
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
J Clin Oncol, 2018 Mar 02
IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
N Engl J Med, 2009 Jan 07
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
Front Oncol, 2020 Jul 16
Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia.
Leukemia, 2021 Jun 26
DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
Haematologica, 2021 Nov 01
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
J Clin Oncol, 2019 Jun 10
Management of Stage II Germ Cell Tumors: Be Sure, Be Patient, Be Safe.
Journal of palliative medicine, 2012-11
Conceptual models for integrating palliative care at cancer centers.
Nature reviews. Clinical oncology, 2016-03
Integrating palliative care into the trajectory of cancer care.
Hered Cancer Clin Pract, 2021 Apr 01
Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?
The American journal of cardiology, 2018-12-01
Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Curr Oncol, 2021 Oct 13
Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors.
Cardiooncology, 2019 Jan 29
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.
Pediatr Transplant, 2021 Aug
Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy.
Br J Haematol, 2023 May 2
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.
Bone marrow transplantation, 2022 Dec 27
CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.
Eur Heart J, 2022 Jan 31
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
J Am Heart Assoc, 2020 Jan 21
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.
Circulation, 2020 Jun 15
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.
Journal of the National Cancer Institute, 2016-06
An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer.
Pediatrics, 2014 Feb 02
Chemotherapy drug shortages in pediatric oncology: a consensus statement.
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
The Journal of urology, 2018-12
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
N. Engl. J. Med.,
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Lancet Oncol., 2014 Feb 18
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
NEJM Evidence, 2022 Jun 1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Br J Cancer, 2014 Apr 15
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Cancer, 2011-06-15
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
Eur J Cancer, 2017 Nov 28
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
N. Engl. J. Med., 2019 Sep 28
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Lancet Oncol, 2021 Jan 18
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
J Clin Oncol, 2021 Apr 19
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
J Clin Oncol, 2003 Jul 01
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
JAMA, 2019 Apr 16
Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial.
Head Neck, 2016 Mar 29
Effectiveness of honey on radiation-induced oral mucositis, time to mucositis, weight loss, and treatment interruptions among patients with head and neck malignancies: A meta-analysis and systematic review of literature.
The Lancet. Oncology, 2017-05
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Haematologica, 2019 Jan 03
The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.
The New England journal of medicine, 2022 Jul 13
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
The New England journal of medicine, 2024 Oct 17
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
JAMA Oncol,
Prolonged Nightly Fasting and Breast Cancer Prognosis.
Aging, 2009-12-31
Fasting and cancer treatment in humans: A case series report.
Cell cycle (Georgetown, Tex.), 2010-11-15
Fasting and differential chemotherapy protection in patients.
BMC cancer, 2016-06-10
Safety and feasibility of fasting in combination with platinum-based chemotherapy.
BMC Cancer, 2015 Oct 05
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.
BMC Cancer, 2018 Apr 27
The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
Int J Radiat Oncol Biol Phys, 2020 Jun 30
ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma.
Contemporary clinical trials, 2017-02
DIETFITS study (diet intervention examining the factors interacting with treatment success) - Study design and methods.
Blood Adv,
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Radiother Oncol, 2021 Dec 7
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Int J Radiat Oncol Biol Phys, 2021 Dec 1
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
Int J Radiat Oncol Biol Phys, 2022 Dec 20
Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.
Transplant Cell Ther, 2022 Dec 30
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Blood advances, 2020 Jul 28
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26
Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.
Blood advances, 2020 Nov 24
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Journal of the National Cancer Institute, 2018-01-01
Use of Alternative Medicine for Cancer and Its Impact on Survival.
JAMA oncology, 2021 May 01
Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial.
Antioxidants & redox signaling, 2020 Aug 07
Vitamin C and Cell Death.
Journal of experimental & clinical cancer research : CR, 2020 Oct 07
Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas.
BMJ (Clinical research ed.), 2000 Nov 04
The role of complementary and alternative medicine.
J Hematol Oncol, 2022 Mar 26
Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Blood advances, 2022 May 10
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.
International journal of radiation oncology, biology, physics, 2005-11-15
Radiation-induced osteosarcomas in the pediatric population.
European journal of cancer (Oxford, England : 1990), 2007 Jan 30
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
JAMA oncology, 2018 Jan 01
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Clin Cancer Res, 2021 Mar 25
Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2021 Feb 25
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2021 May 14
Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.
European journal of cancer (Oxford, England : 1990), 2011 Jun 22
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
JCO oncology practice, 2023 Feb 10
Fertility Preservation Practices at Pediatric Oncology Institutions in the United States: A Report From the Children's Oncology Group.
The New England journal of medicine, 2007-07-26
High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.
Bone marrow transplantation, 2020 Dec 07
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Jul 16
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).
The Lancet. Oncology, 2011 Dec 13
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Transplantation reviews (Orlando, Fla.), 2021 Jun 24
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference.
American journal of hematology, 2016-09
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Blood, 2017 Jun 13
How I treat patients with aggressive lymphoma at high risk of CNS relapse.
N. Engl. J. Med.,
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med,
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Blood, 2009 Mar 10
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 01
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
The New England journal of medicine, 2023 Dec 12
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
The New England journal of medicine, 2016-04-07
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
N Engl J Med, 2023 Jun 04
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Journal of oncology practice, 2018-09-04
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary.
Leukemia & lymphoma, 2022 Mar 15
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
Hematology. American Society of Hematology. Education Program, 2020 Dec 04
Updates in infection risk and management in acute leukemia.
N Engl J Med, 2017 Jun 8
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
The Lancet. Oncology, 2014 Mar 05
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
European journal of cancer (Oxford, England : 1990), 2019 Jan 25
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-20
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.
Blood, 2021 May 13
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
JACC. Heart failure, 2022 Jun 08
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
Cardio-oncology (London, England), 2021 Sep 27
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.
JACC. CardioOncology, 2023 Jun 20
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: Primer.
Medicina oral, patologia oral y cirugia bucal, 2008 Oct 01
Malignant mental nerve neuropathy: systematic review.
Blood, 2023 Mar 23
How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia.
Neuro-oncology advances, 2021 Apr 19
Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.
The New England journal of medicine, 2008-03-27
Hydroxyurea for the treatment of sickle cell anemia.
The New England journal of medicine, 2020 Jun 25
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
Frontiers in genetics, 2022 Aug 26
Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.
Chest, 2012-02
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
N Engl J Med, 2020 Mar 29
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Chest, 2021 Oct 08
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Thrombosis journal, 2017 Oct 03
Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis.
Lupus, 2014 Jul 30
Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections.
MMWR. Morbidity and mortality weekly report, 2024 Sep 12
Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.
Journal of the Endocrine Society, 2022 Dec 02
Perioperative Evaluation and Management of Patients on Glucocorticoids.
Diagnostics (Basel, Switzerland), 2021 Apr 20
Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice.
Blood, 2022 Jun 16
A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
Annals of the rheumatic diseases, 2023 Mar 31
Efficacy and safety of emapalumab in macrophage activation syndrome.
Blood, 2016-03-31
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Bone marrow transplantation, 2016-07
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.
Bone marrow transplantation, 2018-02
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.
British journal of haematology, 2020 Mar 04
Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.
Blood advances, 2022 Jan 11
Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2020 Jan-Dec
A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting.
Bone marrow transplantation, 2022 Dec 23
Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.
American journal of clinical oncology, 2021 Aug 01
Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
Annals of gastroenterology, 2022 Jun 02
infection in cancer patients receiving immune checkpoint inhibitors.
Melanoma research, 2023 Mar 27
Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
Br J Haematol, 2023 Dec 10
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Blood advances, 2024 Jan 09
Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Blood advances, 2023 Apr 11
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2024 Jan 05
PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Int J Radiat Oncol Biol Phys, 2006 Dec 1
Update of human spinal cord reirradiation tolerance based on additional data from 38 patients.
Int J Radiat Oncol Biol Phys, 2019 Oct 10
Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2021 May 05
New clinical data on human spinal cord re-irradiation tolerance.
International journal of radiation oncology, biology, physics, 2013-03-01
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
International journal of radiation oncology, biology, physics, 2020 Jan 24
Randomized, Placebo-Controlled Clinical Trial Combining Pentoxifylline-Tocopherol and Clodronate in the Treatment of Radiation-Induced Plexopathy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2001 Mar
Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy.
Cancer research and treatment, 2006 Dec 31
The effect of pentoxifylline on radiobiological parameters in the rat radiation myelopathy.
European journal of haematology, 2023 Aug 27
Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G-CSF regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-10-20
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Radiation oncology (London, England), 2013 Oct 22
Clinicopathologic features and responses to radiotherapy of myeloid sarcoma.
Cancer, 2023 Jun 24
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
The New England journal of medicine, 2024 Jun 03
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Nature medicine, 2024 Jun 03
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
The New England journal of medicine, 2013-02-21
Apixaban for extended treatment of venous thromboembolism.
The New England journal of medicine, 2017 Mar 18
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Pediatric blood & cancer, 2024 Aug 03
Transfusional hemosiderosis in childhood cancer patients and survivors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Dec 12
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
N Engl J Med, 2022 Nov 03
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.

Related Topics in Medical Oncology

Copyright © 2025 theMednet
All Rights Reserved.